CClinicalTrials.gg
RecruitingNCT05992571Updated Dec 1, 2023

Oral Ketone Monoester Supplementation and Resting-state Brain Connectivity

An interventional study of Placebo and β-OHB in Cerebrovascular Function and Cognition, sponsored by McMaster University. Recruiting at 1 site in Canada. Open to participants aged 55 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by McMaster University · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 2 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
55 Years to 75 Years
Sex
All
01

Study summary

People who report subjective memory complaints have a greater risk of developing dementia. Memory issues may be an early warning sign of dysfunctional cerebral glucose metabolism and cerebral blood flow. Interventions that can restore cerebral metabolism and enhance cerebral blood flow may protect against conversion to dementia. Exogenous ketone supplements have been shown rapidly improves brain network function in young adults. Further, infusion studies demonstrate that ketone bodies enhance cerebral blood flow in cognitively normal adults. Whether acute ketone monoester supplementation can improve brain function in adults with subjective memory complaints is currently unknown.

This study will investigate the effects of a single ketone monoester dose on resting-state functional connectivity in the default mode network and resting cerebral blood flow in adults with subjective memory complaints.

02

Conditions studied

  • Cerebrovascular Function
  • Cognition

Keywords

  • Beta-hydroxybutyrate (β-OHB)
  • cerebral blood flow
  • cognition
  • brain connectivity
03

In context

Lead sponsor

McMaster University is the lead sponsor of 720 studies on the registry; 124 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • between the ages of 55 and 70
  • presence of subjective memory complaints as determined by the Prospective- Retrospective Memory Questionnaire
  • cognitively normal, e.g. score ≥26 on the Montreal Cognitive Assessment

Exclusion criteria

Exclusion Criteria:

  • Presence of obesity (body mass index > 30 kg/m\^2)
  • Presence of known cardiovascular disease
  • Presence of type 2 diabetes
  • History of cardiovascular events requiring hospitalization in the past 3 years (e.g., heart attack, stroke)
  • History of concussion(s) with persistent symptoms
  • Currently following a ketogenic diet and/or taking ketone body supplements
  • Diagnosis of any form of Alzheimer's disease or dementia
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Single dose of a taste-matched calorie-free placebo

    Other: Placebo

  • Experimental
    β-OHB

    Single dose of a ketone monoester (\[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate; 0.6 g β-OHB/kg body weight)

    Dietary Supplement: β-OHB

Interventions

  • OtherPlacebo

    Ingestion of a taste-matched calorie-free placebo drink followed by 90 minutes of rest.

  • Dietary supplementβ-OHB

    Ingestion of a high dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 90 minutes of rest.

06

What researchers measure

Primary outcomes

  1. Brain network connectivity

    Functional connectivity of the default mode network (DMN) is measured via functional MRI. Changes in BOLD signal in each region are determined by independent component analysis and then functional connectivity is measured as a Pearson correlation (r) between the neural regions comprising the DMN and transformed into a z score.

    Time frame: 90 minutes

  2. Cerebral blood flow

    Sum of blood flow in the internal carotid and vertebral arteries via phase contrast MRI in ml/min.

    Time frame: 90 minutes

Secondary outcomes

  1. Working memory

    Computer battery to assess working memory (n-back test) based on N2 reaction time

    Time frame: 90 minutes

  2. Executive function

    Computer battery to assess executive function (Stroop test) based on Stroop Cost (reaction times to incongruent stimuli minus congruent stimuli).

    Time frame: 90 minutes

  3. Attention and working memory

    Computer battery to assess working memory (digit symbol substitution task) based on the number of correct responses in 120 seconds.

    Time frame: 90 minutes

Other outcomes

  1. Mean arterial pressure

    Automated blood pressure cuff measurement of brachial artery pressure in mmHg.

    Time frame: 90 minutes

  2. Plasma beta-hydroxybutyrate

    Measured via finger capillary samples in mM

    Time frame: 90 minutes

07

Study locations

1 of 1 sites recruiting
  • McMaster University
    Hamilton, Ontario L8S 4K1, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The investigators will share individual patient data (de-identified) with researchers upon request.

Supporting information: Study protocol, Sap, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05992571
Lead sponsor
McMaster University
Collaborators
Alzheimer's Society of Brant, Haldimand Norfolk, Hamilton Halton
Responsible party
Jeremy Walsh (Assistant Professor, McMaster University) — Principal investigator
First posted
Aug 15, 2023
Start date
Oct 25, 2023
Primary completion
Aug 2024 (estimated)
Completion
Aug 2024 (estimated)
Last update
Dec 1, 2023

Study contacts

Jeremy Walsh, PhD
Contact
walshj18@mcmaster.ca
905-525-9140 ext. 23523
Jeremy Walsh, PhD
principal investigator · McMaster University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion